Iterum Therapeutics plc Ordinary Share earnings per share and revenue
On 14 de nov. de 2025, ITRM reported earnings of -0.20 USD per share (EPS) for Q3 25, missing the estimate of -0.11 USD, resulting in a -78.25% surprise. Revenue reached 390.00 mil, compared to an expected --, with a 0.00% difference. The market reacted with a -16.11% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 4 analistas forecast an EPS of -0.09 USD, with revenue projected to reach 3.07 milhão USD, implying an diminuir of -55.00% EPS, and aumentar of 685.92% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Citius Pharmaceuticals Inc. Common
Report Date
26 de dez. de 2025 Para Q4 25
Estimativa
-$0.49
Real
-
Surpresa
-
FAQ
What were Iterum Therapeutics plc Ordinary Share's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Iterum Therapeutics plc Ordinary Share reported EPS of -$0.20, missing estimates by -78.25%, and revenue of $390.00K, 0% as expectations.
How did the market react to Iterum Therapeutics plc Ordinary Share's Q3 2025 earnings?
The stock price moved down -16.11%, changed from $0.56 before the earnings release to $0.47 the day after.
When is Iterum Therapeutics plc Ordinary Share expected to report next?
The next earning report is scheduled for 05 de fev. de 2026.
What are the forecasts for Iterum Therapeutics plc Ordinary Share's next earnings report?
Based on 4
analistas, Iterum Therapeutics plc Ordinary Share is expected to report EPS of -$0.09 and revenue of $3.07M for Q4 2025.